Dual Raltegravir/Etravirine Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy

  title={Dual Raltegravir/Etravirine Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy},
  author={Ruxandra Calin and Luc Paris and Anne Simon and Gilles Peytavin and Marc Wirden and Luminita Schneider and Marc Antoine Valantin and Roland Tubiana and Rachid Agher and Christine Katlama},
  journal={Antiviral Therapy},
  pages={1601 - 1604}
Background The combination of raltegravir (RAL) and etravirine (ETR) represents a novel antiretroviral treatment option in patients with toxicity or long-term exposure to standard therapies including protease inhibitors (PI) and nucleoside reverse transcriptase inhibitors (NRTI). The objective of this study was to evaluate the capacity of dual RAL/ETR therapy to maintain virological suppression in HIV-1 patients under effective antiretroviral therapy (ART). Methods Using the Nadis database we… 

Tables from this paper

Dual Raltegravir-Etravirine Combination as Maintenance Regimen in Virologically Suppressed HIV-1-Infected Patients.

In this study, simplification to the dual-therapy raltegravir plus etravirine was associated with a good efficacy and tolerability, in addition to a favorable effect on kidney, bone, and serum lipids.

Nevirapine–Raltegravir Combination, An Nrti and Pi/R Sparing Regimen, as Maintenance Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients

In patients with prolonged HIV-1 RNA<50 copies/ml, switching to NVP-RAL combination maintained virological suppression throughout 36 months and deserves further evaluation in patients unable to tolerate NRTI or PI/ritonavir agents.

Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study.

Dual therapy with etravirine plus raltegravir was well tolerated and maintained durable viral suppression in selected virologically suppressed patients for whom both PI and NRTI therapy was challenging.

Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIV-1-infected patients

This study shows that in ART-experienced patients ETR is well tolerated with a high efficacy when combined with other active drugs, even when the regimen does not include a bPI.

Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study.

Raltegravir plus etravirine dual therapy demonstrated durable efficacy in virologically suppressed ageing patients in a 96-week, multicentre, single-arm study.

The use of nucleoside reverse transcriptase inhibitors sparing regimens in treatment-experienced HIV-1 infected patients.

There was no difference between groups in terms of total withdrawal, treatment discontinuation was more likely due to therapeutic failure in N RTI-sparing regimen, and NRTI- Sparing regimens should be evaluated in a prospective randomized trial.

Effectiveness and safety of dual therapy with rilpivirine and boosted darunavir in treatment-experienced patients with advanced HIV infection: a preliminary 24 week analysis (RIDAR study)

Dual therapy with RPV + DRVb proved to be effective and safe in patients with advanced HIV infection, long exposure to ART, low CD4 nadir, previous virologic failure, and/or history of ineffective ART.

Antiretroviral drug reduction in highly experienced HIV-infected patients receiving a multidrug regimen: the ECOVIR study.

In experienced patients with high-level resistance, individualized strategies based on expert advice can offer DR regimen options with fewer drug-drug interactions and a significant economic impact while ensuring virological success.

Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials

A possible new role for etravirine, in combination with two nucleoside analogues, as a switching option for those with HIV RNA suppression but who are reporting adverse events possibly related to antiretroviral therapy is suggested, however a large well-powered trial would need to be conducted to strengthen the evidence.

High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.

  • Y. YazdanpanahC. Fagard G. Chêne
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2009
In patients infected with multidrug-resistant virus who have few remaining treatment options, the combination of raltegravir, etravirine, and darunavir/ritonavir is well tolerated and is associated with a rate of virologic suppression similar to that expected in treatment-naive patients.

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study

In patients with sustained virological suppression on ritonavir-boosted protease inhibitor-based therapy, switching to raltegravir demonstrated noninferior efficacy and resulted in a better lipid profile at 48 weeks than continuing riton Cavir- boosted protease inhibitors.

Etravirine-raltegravir, a marked interaction in HIV-1-infected patients: about four cases.

Maraviroc has been tested in a recent nonrandomized, prospective, open-label, proof-of-concept pilot study with a minimum follow-up of 150 days, and although two patients showed dramatic increases in CD4 cell counts, the average change was þ14 cells for all patients, and was not statistically significant (P> 0.39).

Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials

Etravirine, in combination with an antiretroviral background regimen, provided durable virological and immunological responses with no new safety concerns in treatment-experienced patients over 96 weeks in the DUET trials.

Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.

  • J. RockstrohJ. Lennox P. Sklar
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2011
When combined with tenofovir/emtricitabine in treatment-naive patients, raltegravir produced durable viral suppression and immune restoration that was at least equivalent to efavirenz through 156 weeks of therapy.

Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients

Ten HIV-1-infected patients with multiple treatment failure received raltegravir and darunavir/ritonavir and all pharmacokinetic parameters appeared to be highly variable regardless to the addition of etravirine.

Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial.

In the SENSE trial, first-line treatment with 400 mg of etravirine once daily plus two nucleoside analogues led to fewer grade 3 or 4 lipid elevations compared with efavirenz plus three nucleosid analogues.

A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population

After 12 weeks, first-line treatment with etravirine 400 mg once daily with two NRTIs was associated with significantly fewer neuropsychiatric adverse events when compared with efavirenz with twoNRTIs.

Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies

  • D. Burger
  • Medicine, Biology
    Expert opinion on drug metabolism & toxicology
  • 2010
Raltegravir is a welcome addition to the antiretroviral drug armamentarium due to its good tolerability, low potential for drug–drug interactions and good clinical efficacy in both treatment-naive and -experienced patients.